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SUMMARY
Objective: The aim of this investigation was to  
compare the pharmacokinetics of lidocaine and 
prilocaine in two groups of 10 patients under­
going intravenous regional anaesthesia.
Method: The study had a randomized design. The 
patients were allocated to one of the two groups 
of 10. Each group received either lidocaine 
(200 mg = 0*855 h im ) or prilocaine (Citanest®, 
200 m g = 0*909 m M ), injected intravenously over a 
period of 30 s. Onset of the surgical analgesia was 
defined as the period from the end of the injection 
of the local anaesthetic to the loss of pinprick 
sensation in the distribution of all three nerves. 
Results: The mean onset time of surgical analgesia 
of lidocaine was 11-2 ±  5*1 min and that of prilo­
caine was 10*9 ± 6*0  min. After releasing the 
tourniquet, lidocaine is bi-exponentially elimi­
nated with a t lj2a of 4*3 ±  2*1 min and a t lf2/} 
of 79*1 ±  31*2 min. Total body clearance was 
0*86 dt 0*39 litres/min. Prilocaine is rapidly and 
bi-exponentially eliminated with a of
3*0 ±  1*6 min and a t ll2  ^ o f 29-9 ± 1 5 * 7  min. 
The total body clearance of prilocaine is higher 
than that of lidocaine, 4*15 ±  1-31 vs. 
0*86 ±  0*39 litres/min, respectively (P = 0*0007). 
Both compounds show comparable volumes of 
distribution (Fd, Vsa and Vp) and a comparable 
*1/2« (4*3 db 2*1 vs. 3*0 ±  1*6 min; P=  0*1780). The 
np  f ° r the two compounds were different 
(P=0031); 79*1 ±  31*2 min for lidocaine and
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29*9 ±  15*7 min for prilocaine. The mean resi­
dence time (MRT) of lidocaine (193 ±  233 min) 
also differed significantly from that of prilocaine 
(33*4 ±  19*9 min; P=0*0022).
Conclusion: Lidocaine is preferred for rela­
tively long procedures and prilocaine for short 
procedures.
IN TRO D U CTIO N
Intravenous regional anaesthesia (IVRA), first 
described by Bier in 1908 (1), remains a popular 
technique for short-lasting surgical procedures on the 
hand and forearm and, to a lesser extent, on the lower 
limbs, especially if a tourniquet is to be applied.
Good surgical anaesthesia is achieved quickly fol­
lowing injection of the local anaesthetic agent and 
recovery after release of the tourniquet is rapid. The 
method is safe provided a suitable local anaesthetic 
agent is used. Bupivacaine, for instance, is contra­
indicated because of its cardiotoxicity (2—5), Lidocaine 
and prilocaine are considered to be very suitable 
agents for IVRA (6—14). It is considered to be import­
ant for patients to leave hospital free of anaesthetic 
drugs (15, 16).
Little has been published on the pharmacokinetics 
of lidocaine and prilocaine during IVRA. Both com­
pounds are eliminated by hydrolysis of the amide 
bond, which is quicker with prilocaine than with 
lidocaine due to the 2 ,6 -methyl substitution in the 
phenyl moiety of the latter drug. The aim of this 
investigation was to compare the pharmacokinetics of 
lidocaine and prilocaine in two groups of 10 patients 
undergoing intravenous regional anaesthesia.
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MATERIALS AND METHODS
Patients
The study was approved by the Hospital Ethics 
Committee of the Medisch Spectrum Twente, and
Pharmacopaea. Forty millilitres of the lidocaine 0-5% 
solution (40 x 5 mg/ml—200 mg — 0-855 mM) were 
injected intravenously (i.v.) over a period of 30 s to 
each of the patients in the lidocaine group. Prilocaine 
0 -5% (Citanest(ll)) was obtained from Astra Pharma-
written informed consent to participate was obtained ceuticals (Rijswijk, the Netherlands). Forty millilitres
from 20 patients scheduled for surgery of the hand or of the prilocaine 0-5% solution (40 x 5 mg/ml
group
forearm. All patients were classified according to the 200 mg —0*909 mM) were injected i.v. over a period 
criteria of the American Society of Anesthesiologists of 30 s into each of the patients in the prilocaine 
as ASA I or II. Four men and six women received 
prilocaine. The mean ( =b SD) body weight was 
80-1 ±  15*7 kg, and age 44*1 ±  14-2 years. Three men 
and seven women received lidocaine. The mean 
( ±  SD) body weight was 72-9 ±  12-5 kg, and age 
42*6 ±  12-8 years. The study used a double-blind, 
randomized design.
Patient preparation
No pre-medication was given. An 18G cannula was 
introduced into a suitable vein in the dorsum of the 
hand of the arm to be treated. Two cannulae were 
introduced into the other arm, one into a suitable vein 
and the other into the radial artery. The latter was 
used for continuous monitoring of blood pressure and 
for intermittent blood sampling.
Oxygen saturation via a Datex 'Satlite (Datex 
Division of Instrumentarium, Helsinki, Finland), pulse 
rate and EKG pulse-oximeter (three-lead, I, II and III 
via HP 78353 B, Andover, U.S.A.) and arterial blood 
pressure were measured continuously from the first 
venous cannulation until withdrawal of the final blood 
sample. A 12-lead electrocardiogram was registered on 
a Hellige Mulfcis crip tor EK 33 (Hellige, Freiburg, 
Germany) in all patients prior to injection of the local 
anaesthetic and 5 and 15 min after deflation of the 
tourniquet.
The arm was exsanguinated by means of an 
Esmarch bandage, after which a pneumatic tourniquet, 
placed around the arm above the elbow was inflated to 
150 Torr above normal systolic pressure or 300 Torr, 
whichever was higher. The local anaesthetic was 
injected intravenously in a randomized, double-blind 
fashion for establishing efficacy.
Drugs
Lidocaine 0*5% was prepared in the Department of 
Pharmacy of the Medisch Spectrum Twente (Enschede, 
the Netherlands) following the criteria of the Dutch
Si de'■effects
Any skin reactions or subjective complaints were 
noted. The development of sensory blockade over the 
distributions of the median, radial and ulnar nerves 
was assessed by pinprick. Onset of the surgical 
analgesia was defined as the period from the end of 
the injection of the local anaesthetic to the loss of 
pinprick sensation in the distribution of all three 
nerves.
Sampling
A total of 15 arterial blood samples were taken from 
each patient. One was drawn immediately before 
injection and subsequent samples at 10-min intervals, 
commencing 10 min after completion of the injection 
and ending at the moment of release of the tourniquet. 
The latter time was registered as t = 0 , and arterial 
blood samples were drawn at 1, 5, 10, 15, 20, 25, 30, 
45, 60, 75 and 90 min. In no case was the tourniquet 
released within 30 min of completing the injection. 
Blood was collected in tubes containing Li-heparin, 
The samples were centrifuged at 3000 g, and 
the plasma separated and stored at — 20 °C until 
analysis.
Analysis
The plasma concentration of ( ±  )prilocaine 
(C13H20N20 :  CAS number 721-50-6, molecular 
weight =220*31, pXa=7*9; HCI salt: CAS number 
1786-81-8, molecular weight = 256'S) was determined 
by high-performance liquid chromatography (HPLC) 
using a modification of the method described by 
Lindberg and Pilhlajmaki (17). Briefly, the method is as 
follows. Column: Spherisorb 5 ODS, 250 x 4-6 mm. 
UV detection was achieved at 230 nm. Mobile phase
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(4 g H3P 0 4, 0'6  g TMAC1 in 1 litre water) and 
acetonitrile (4:6 v/v) at 1*5 ml/min flow rate. Plasma 
(0*3 ml) was deproteinized with 0-33 M perchloric acid 
(0*3 ml), vortexed and centrifuged at 3000 g. Fifty 
microlitres were injected onto the column. The limit 
of quantitation was 0*1 (ig/mL The inter- and intra­
day coefficients of variance for prilocaine were less 
than 5%,
The plasma concentration of lidocaine (CI4H 22N 20 :  
CAS number 137-58-6, molecular weight =234-33; 
HC1.H20  salt: CAS number 73-78-9, molecular weight 
=288-8) was determined by the same method. Ultra­
violet detection was achieved at 210  nm. The inter- 
and intra-day coefficients of variance for lidocaine 
were less than 5%.
Pharm acokinetics
Pharmacokinetic parameters were calculated using 
a two-compartment model with the MW/Pharm 
computer package (Mediware0^ , Groningen, the 
Netherlands) (18).
Cm ax was the maximum plasma concentration read 
from the fitted plasma concentration-time curve 
(r2>0-98), and ¿max the time at which Cmax occurred. 
The elimination half-life {t 1}z values were calculated 
from ln2//?, where fi was calculated by log-linear 
regression analysis of the terminal log-linear phase. 
AU C0_t was the area under the plasma concentration- 
time curve and was calculated using the linear trap­
ezoidal rule and Cf J3, with Ct (f= 90) being the last
measured concentration.
Total body clearance (Cl) is described as dose/
AUC
0 - 1 '
dose/C O' the volume of distribution in the
central compartment
Vp— CUP, the volume of distribution in the second 
compartment.
Vss=dose A U M C 0j A U C 0_f2f
distribution at steady state.
Mean residence time (MRT)1
the volume of
A U M C 0J A U C 0_t*
where A U M C 0_{ is the area under the moment 
curve from zero to ¿•=90.
-40 -20 0 20 40 
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Fig. 1 . Mean plasma concentrati on-time curves of lido­
caine (L) and prilocaine (P) after a regional i.v. dose of 
200 mg (n = 10). During tourniquet occlusion there were no 
measurable plasma concentrations at the quantification limit 
of 0*1 U-j
Clinical response
The mean onset time of surgical analgesia of lido­
caine was 11*2 ± 5 -1  min and that of prilocaine 
10-9 ±  6*0 min (P=04236). There was im  
towards a fixed sequence, radial, median, ulnar in -the 
development of sensory blockade. In all patients 
satisfactory surgical conditions, evidenced by good 
•sensory blockade, were reached within 20 mki 
additional analgesics were required. None of the 
patients exhibited objective symptoms of toxicity, 
either local or systemic, during injection of the local 
anaesthetic, nor were there any subjective consplaioihs. 
No changes in blood pressure, heart rate or oxygen 
saturation were observed at any time during the 
procedure, nor after deflation of the tourniquet.
ao
St a Hstical ana lysis
The Mann-Whitney two-tailed test for 
observations was used. Statistical significance was 
defined as P < 005 .
Pharmacokin eiics
Figure 1 shows the mean plasma concentration-time 
curves of lidocaine and prilocaine in 10 patients after 
releasing the tourniquet. Plasma concentrations were
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Table 1. M ean plasma concentrations (|lg/m l ±  SD) of 
lidocaine and prilocaine after IVRA administration of 40 ml 
of 0-5% =200 mg
Time* (min) Lidocaine Prilocaine
1 4-70 ±  2*14 3-36 ± 0 -9 6
5 2*88 ±  0-96 1-94 ± 0 -5 3
10 2*18 ±  0*60 107  ±  0 ’23
15 1 *79 ±  0*40 0-78 ± 0 -1 6
20 1-59 ± 0 -3 7 0-54 ±  0-07
25 1-37 ± 0 -1 9 0‘49 ±  0*15
30 1-33 ±  0*07 0-43 ±  0-19
35 1-14 ±0*24 0-30 ±  0-15
60 1*01 ±  0*26 0 2 5  ±  0-05
75 0-90 ± 0 -2 7 0*22 ±  0-07
90 0-79 ±  0*19 0*15 ±  0-05
*Time — after tourniquet release. 
Limit of quantification =0-1 (ig/ml.
zero before releasing the tourniquet and rose immedi­
ately to maximal concentrations after 1 min (Table 1). 
The elimination of lidocaine is bi-exponential, with a 
t-ilza 4*3 ±  2-1 min and a k1/1p of 79*1 ±  31-2 min. 
The elimination of prilocaine is bi-exponential, with a 
hlia  3-0 ±  1*6 min and a k1}2p of 29-9 ±  15-7 min.
Table 2 shows the mean values and statistical 
differences in the pharmacokinetic parameters of lido­
caine and prilocaine. The total body clearance of 
prilocaine is higher than that of lidocaine, 4-15 ±  1-31 
vs. 0-86 ±  0*39 litres/min, respectively (P=0*0007). 
Both compounds show comparable volumes of distri­
bution (Vd, Vss and Vp) and a comparable f1/2a 
(4*3 ±  2-1 vs. 3*0 ±  1-6 min; P=0-1780). The t1¡2p 
differs significantly between the two compounds 
(P= 0*031); 79-1 dh 31*2 min for lidocaine and 
29.9 ±  X5*7 min for prilocaine. The MRT of lidocaine 
(193 ± 2 3 3  min) also differs significantly from that of 
prilocaine (33-4 ±  19*9 min; P =  0 *0022).
DISCUSSION
Diverse local anaesthetic agents have been used for 
IVRA. At the beginning of the 2 0 th century, Bier (1) 
used 40 ml 0-5% procaine. The use of prilocaine was 
first reported by Lofgren and Tegner in I960 (19). The 
use of chloroprocaine and lidocaine were first used in 
1963 (20 ). Injection of chloroprocaine may lead to
Table 2. Comparison of the pharmacokinetic parameters 
(mean ±  SD) of lidocaine and prilocaine after IVRA admin­
istration of 40 ml of 0-5% “ 200 mg
Parameter Lidocaine Prilocaine P
Subjects M/F 3/7 4/6
Body weight (kg) 72-9 ±  12*5 80*1 ±  15*7 0.5217




A U C  (mg/litre/min) 127 ±  23-1 45*4 ±  11-5 0*0007
Cl (litres/min) 0*86 ±  0*39 4*15 ±  1*31 0*0007
Vd (litres) 30*2 ±  3*91 51-4 ±22*8 0*1632
Kss (litres) 104 ±  37*7 120 ±  49-4 0*5907
Vp (litres) 105 ±  27*6 158 ± 55-8 0'0723p
til2a (min) 4*30 ±2*12 3*04 ±  1*62 0*1780
h i2/3 (min) 79-1 ±  31*2 29*9 ±  15*7 0*0031
MRT (min) 193 ±  233 33*4 ±  19-9 0*0022
P—Mann—Whitney two-tailed test.
thrombophlebitis (2 1 ), venous irritation and urticaria 
(22 ). Bupivacaine is contraindicated because of poten­
tial cardiotoxicity, and fatal complications have been 
reported following intravenous injection (2-5), a situ­
ation which occurs with this technique when the 
tourniquet is released, The ideal agent for IVRA 
should achieve rapid onset of good surgical anesthesia 
and, above all, be safe. Lidocaine and ( ±  )prilocaine 
both fulfil these criteria, as reported by several authors 
(7, 12-14, 22-28).
The flushing and absorption of both lidocaine and 
prilocaine from the exsanguinated forearm after releas­
ing the tourniquet was so fast that the maximum 
plasma concentration was detected in the first sam­
pling time at 1 min The maximum plasma concen­
trations of lidocaine were in agreement with those 
reported earlier (9, 29, 30) and stayed well below the 
toxic concentrations of 5 -1 0  |lg/ml, depending on the 
degree of anaesthesia (31).
Thereafter, lidocaine was eliminated according to a 
bi-exponential decay after i.v. administration with a 
tii2a of 4-3 ±  2-1 min and a t1/2p of 79*1 ±  31*2 min. 
Prilocaine was also eliminated according to a 
bi-exponential decay after i.v. administration with 
a tl/2a of 3*0 ±  1-6 min and a p of 29-9 ±15*7 min. 
The pharmacokinetic data shown in Table 2 
correspond with those previously reported (32, 33).
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The difference between the pharmacokinetics of 
lidocaine and prilocaine can be attributed solely to the 
difference in t1/2ß values, which affects the A U C t and 
thus the total body clearance. The rates of distribution 
and volumes of the two compounds are similar. The 
rate of metabolism/hydrolysis governs the overall rate 
of elimination, which is greater with prilocaine.
Comparison of metabolism
The metabolism of lidocaine proceeds via cytochrome 
P450 isoenzymes resulting in N-hydroxylation, 
N-dealkylation (MEGX, GX) and the principal reac­
tion of 4-hydroxylation (32—36). The metabolism of 
prilocaine proceeds via cytochrome P450 iso­
enzymes resulting in N-hydroxylation, N-dealkylation 
(N-propylalanine) and hydrolysis of the amide bond 
(O-toluidine) (32—39). Unless tissue cytochrome P450 
is capable of performing such reactions in measurable 
quantities, it is unlikely that a substantial amount of 
either lidocaine or prilocaine will be metabolized in the
30 min duration of exsanguination of the forearm.
CONCLUSIONS
It was concluded that both lidocaine and prilocaine are 
suitable and safe agents for IVRA with rapid onset of 
good surgical anaesthesia. This is in line with every­
day practice in most institutions. After releasing the 
tourniquet, prilocaine is rapidly eliminated with a tljl ß 
of 30 min, while lidocaine is eliminated more slowly 
with a tjjzß of SO min
The longer elimination time of lidocaine results in a 
longer MRT than that of prilocaine. This apparently 
insignificant difference between the two drugs may 
well have important clinical consequences. Depending 
on the expected time-course of the surgical procedure 
(2^/2 /j), lidocaine or prilocaine can be the drug of 
choice for a local anaesthetic action. For a short- 
lasting surgical procedure ( ±  )prilocaine is the local 
anaesthetic of choice (2tt f2 ß —60 min), although 
administration of a racemic mixture is nowadays 
considered less favourably, while for a longer-lasting 
procedure lidocaine is preferred (2t1/z ß= 160 min).
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